Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature

Andrikopoulou,Angeliki; Goga,Kristiana; Stefanaki,Katerina; Paschou,Stavroula A.; Athanasopoulos,Stavros; Zagouri,Flora; Dimopoulos,Meletios-Athanasios

doi:10.3892/ol.2024.14550

Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature

Authors:
- Angeliki Andrikopoulou
- Kristiana Goga
- Katerina Stefanaki
- Stavroula A. Paschou
- Stavros Athanasopoulos
- Flora Zagouri
- Meletios-Athanasios Dimopoulos
View Affiliations

Affiliations: Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece, Department of Clinical Therapeutics, Endocrine Unit and Diabetes Centre, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
Published online on: July 1, 2024 https://doi.org/10.3892/ol.2024.14550
Article Number: 417

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cushing's syndrome (CS), as a result of ectopic adrenocorticotropic hormone (ACTH) production, constitutes a common paraneoplastic manifestation of various malignancies, with the most common being small cell lung carcinoma. In the literature, fewer than fifty cases associating ectopic CS with prostate cancer have been documented. In the present study, the case of a 76‑year old man suffering from castration‑resistant prostate adenocarcinoma that had been treated with enzalutamide and luteinizing hormone‑releasing hormone (LHRH) analogue for the last four years is presented. The patient presented to the emergency department with lower extremity muscle weakness, bradypsychia and hypokalemia. Following a thorough diagnostic evaluation, hypercortisolemia was identified. No suppression after low‑ and high‑dose dexamethasone challenge, increased cortisol 24 h excretion and normal pituitary magnetic resonance imaging led to the diagnosis of ectopic CS. Immediate targeted therapy was initiated with adrenal steroidogenesis inhibitors, including metyrapone and ketoconazole along with chemotherapy with docetaxel and prednisolone. There was a remarkable decrease in cortisol levels within days and hospitalization was no longer required. The patient managed to complete three cycles of chemotherapy; unfortunately, he succumbed within three months of the diagnosis of ectopic CS. In the present study, all existing cases of paraneoplastic CS related to prostate cancer are reviewed. The aim of the current study was to highlight the need of early diagnosis and treatment of this entity as it may present with atypical clinical findings and potentially evolve to a life‑threatening condition.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, et al: 2022 update on prostate cancer epidemiology and risk Factors-A systematic review. Eur Urol. 84:191–206. 2023. View Article : Google Scholar : PubMed/NCBI
3	Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J, Perner S, Pantel K, Werner S and von Amsberg G: Aggressive variants of prostate cancer: Underlying mechanisms of neuroendocrine transdifferentiation. J Exp Clin Cancer Res. 41:462022. View Article : Google Scholar : PubMed/NCBI
4	Gupta K and Gupta S: Neuroendocrine differentiation in prostate cancer: Key epigenetic players. Transl Cancer Res. 6 (Suppl 1):S104–S108. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hu CD, Choo R and Huang J: Neuroendocrine differentiation in prostate cancer: A mechanism of radioresistance and treatment failure. Front Oncol. 5:902015. View Article : Google Scholar : PubMed/NCBI
6	Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M and Habra MA: Cushing's syndrome secondary to ectopic ACTH secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer. 117:4381–4389. 2011. View Article : Google Scholar : PubMed/NCBI
7	Matzkin H and Braf Z: Paraneoplastic syndromes associated with prostatic carcinoma. J Urol. 138:1129–1133. 1987. View Article : Google Scholar : PubMed/NCBI
8	Dhom G: Unusual prostatic carcinomas. Pathol Res Pract. 186:28–36. 1990. View Article : Google Scholar : PubMed/NCBI
9	Yonaha M, Tanaka M, Kawano T, Sugiyama M, Nishikawa T and Sasano K: An autopsy case of ACTH producing prostate neoplasms with Cushing's syndrome. Nihon Naika Gakkai Zasshi. 81:2005–2006. 1992.(In Japanese). View Article : Google Scholar : PubMed/NCBI
10	Ciudin A, Huguet Perez J, Ribal Caparros MJ and Alcaraz Asensio A: Cushing syndrome and prostate cancer recurrence with undetectable prostate-specific antigen. Med Clin (Barc). 140:430–431. 2013.(In Spanish). View Article : Google Scholar : PubMed/NCBI
11	Wenk RE, Bhagavan BS, Levy R, Miller D and Weisburger W: Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer. 40:773–778. 1977. View Article : Google Scholar : PubMed/NCBI
12	Vuitch MF and Mendelsohn G: Relationship of ectopic ACTH production to tumor differentiation: A morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer. 47:296–299. 1981. View Article : Google Scholar : PubMed/NCBI
13	Carey RM, Varma SK, Drake CR, Thorner MO, Kovacs K, Rivier J and Vale W: Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N Engl J Med. 311:13–20. 1984. View Article : Google Scholar : PubMed/NCBI
14	Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A, Grino M, Grimelius L, Hedeland H and Falkmer S: Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh). 119:506–516. 1988.PubMed/NCBI
15	Haukaas SA, Halvorsen OJ, Nygaard SJT and Paus E: Cushing's syndrome in prostate cancer. An aggressive course of prostatic malignancy. Urol Int. 63:126–129. 1999. View Article : Google Scholar : PubMed/NCBI
16	Rickman T, Garmany R, Doherty T, Benson D and Okusa MD: Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis. 37:838–846. 2001. View Article : Google Scholar : PubMed/NCBI
17	Johnson TN and Canada TW: Etomidate use for Cushing's syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor. Ann Pharmacother. 41:350–353. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kataoka K, Akasaka Y, Nakajima K, Nagao K, Hara H, Miura K and Ishii N: Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy. Int J Urol. 14:436–439. 2007. View Article : Google Scholar : PubMed/NCBI
19	Nimalasena S, Freeman A and Harland S: Paraneoplastic Cushing's syndrome in prostate cancer: A difficult management problem. BJU Int. 101:424–427. 2008. View Article : Google Scholar : PubMed/NCBI
20	Alwani RA, Neggers SJ, van der Klift M, Baggen MG, van Leenders GJ, van Aken MO, van der Lely AJ, de Herder WW and Feelders RA: Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. Pituitary. 12:280–283. 2009. View Article : Google Scholar : PubMed/NCBI
21	Rajec J, Mego M, Sycova-Mila Z, Obertova J, Brozmanova K and Mardiak J: Paraneoplastic Cushing's syndrome as the first sign of progression of prostate cancer. Bratisl Lek Listy. 109:362–363. 2008.PubMed/NCBI
22	Alshaikh OM, Al-Mahfouz AA, Al-Hindi H, Mahfouz AB and Alzahrani AS: Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer. Endocr Pract. 16:249–254. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ramon I, Kleynen P, Valsamis J, Body JJ and Karmali R: Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: Cure after bilateral adrenalectomy. Calcif Tissue Int. 89:442–445. 2011. View Article : Google Scholar : PubMed/NCBI
24	Rueda-Camino JA, Losada-Vila B, De Ancos-Aracil CL, Rodríguez-Lajusticia L, Tardío JC and Zapatero-Gaviria A: Small cell carcinoma of the prostate presenting with Cushing Syndrome. A narrative review of an uncommon condition. Ann Med. 48:293–299. 2016. View Article : Google Scholar : PubMed/NCBI
25	Shrosbree J, Pokorny A, Stone E, Epstein R, Mccormack A and Greenfield JR: Ectopic Cushing syndrome due to neuroendocrine prostatic cancer. Intern Med J. 46:630–632. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ramalingam S, Eisenberg A, Foo WC, Freedman J, Armstrong AJ, Moss LG and Harrison MR: Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. Int J Urol. 23:1038–1041. 2016. View Article : Google Scholar : PubMed/NCBI
27	Elston MS, Crawford VB, Swarbrick M, Dray MS, Head M and Conaglen JV: Severe Cushing's syndrome due to small cell prostate carcinoma: A case and review of literature. Endocr Connect. 6:R80–R86. 2017. View Article : Google Scholar : PubMed/NCBI
28	Murphy N, Shen J, Shih A, Liew A, Khalili H, Yaskiv O, Katona K, Lee A and Zhu XH: Paraneoplastic syndrome secondary to treatment emergent neuroendocrine tumor in metastatic Castration-resistant prostate cancer: A unique case. Clin Genitourin Cancer. 17:e56–e60. 2019. View Article : Google Scholar : PubMed/NCBI
29	Kleinig P and Russell P: Lesson of the month 2: An unusual cause of depression in an older man: Cushing's syndrome resulting from metastatic small cell cancer of the prostate. Clin Med (Lond). 18:432–434. 2018. View Article : Google Scholar : PubMed/NCBI
30	Klomjit N, Rowan DJ, Kattah AG, Bancos I and Taler SJ: New-Onset resistant hypertension in a newly diagnosed prostate cancer patient. Am J Hypertens. 32:1214–1217. 2019. View Article : Google Scholar : PubMed/NCBI
31	Soundarrajan M, Zelada H, Fischer JV and Kopp P: Ectopic adrenocorticotropic hormone syndrome due to metastatic prostate cancer with neuroendocrine differentiation. AACE Clin Case Reports. 5:e192–e196. 2019. View Article : Google Scholar : PubMed/NCBI
32	Schepers LM, Kisters JMH, Wetzels C and Creemers GJ: Hypokalaemia and peripheral oedema in a Cushingoid patient with metastatic prostate cancer. Neth J Med. 78:401–403. 2020.PubMed/NCBI
33	Riaza Montes M, Arredondo Calvo P and Gallego Sánch JA: Small cell metastatic prostate cancer with ectopic adrenocorticotropic hormone hypersecretion: A case report. Ann Palliat Med. 10:12911–12914. 2021. View Article : Google Scholar : PubMed/NCBI
34	Fernandes R, Dos Santos J, Reis F and Monteiro S: Cushing syndrome as a manifestation of neuroendocrine prostate cancer: A rare presentation within a rare tumor. Cureus. 13:e181602021.PubMed/NCBI
35	Zeng W and Khoo J: Challenging case of ectopic ACTH secretion from prostate adenocarcinoma. Case Rep Endocrinol. 2022:37399572022.PubMed/NCBI
36	Hassan B, Yazbeck Y, Akiki V, Salti I and Tfayli A: ACTH-secreting metastatic prostate cancer with neuroendocrine differentiation. BMJ Case Rep. 15:e2479972022. View Article : Google Scholar : PubMed/NCBI
37	Newmark SR, Dluhy RG and Bennett AH: Ectopic adrenocorticotropin syndrome with prostatic carcinoma. Urology. 2:666–668. 1973. View Article : Google Scholar : PubMed/NCBI
38	Webster GD Jr, Touchstone JC and Suzuki M: Adrenocortical hyperplasia occurring with metastatic carcinoma of the prostate: Report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. J Clin Endocrinol Metab. 19:967–979. 1959. View Article : Google Scholar : PubMed/NCBI
39	Lovern WJ, Fariss BL, Wettlaufer JN and Hane S: Ectopic ACTH production in disseminated prostatic adenocarcinoma. Urology. 5:817–820. 1975. View Article : Google Scholar : PubMed/NCBI
40	Slater D: Carcinoid tumour of the prostate associated with inappropriate ACTH secretion. Br J Urol. 57:591–592. 1985. View Article : Google Scholar : PubMed/NCBI
41	Molland EA: Prostatic adenocarcinoma with ectopic ACTH production. Br J Urol. 50:358. 1978. View Article : Google Scholar : PubMed/NCBI
42	Wise HM, Pohl AL, Gazzaniga A and Harrison JH: Hyperadrenocorticism associated with ‘reactivated’ prostatic carcinoma. Surgery. 57:655–664. 1965.PubMed/NCBI
43	Ghali VS and Garcia RL: Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature. Cancer. 54:1043–1048. 1984. View Article : Google Scholar : PubMed/NCBI
44	Hussein WI, Kowalyk S and Hoogwerf BJ: Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: Therapeutic response to ketoconazole. Endocr Pract. 8:381–384. 2002. View Article : Google Scholar : PubMed/NCBI
45	Statham BN, Pardoe TH and Mir MA: Response of ectopic prostatic ACTH production to metyrapone. Postgrad Med J. 57:467–468. 1981. View Article : Google Scholar : PubMed/NCBI
46	Hall TC: Symptomatic hypokalemic alkalosis in hyperadrenocorticism secondary to carcinoma of the prostate. Cancer. 21:190–192. 1968. View Article : Google Scholar : PubMed/NCBI
47	Balestrieri A, Magnani E and Nuzzo F: Unusual Cushing's syndrome and hypercalcitoninaemia due to a small cell prostate carcinoma. Case Rep Endocrinol. 2016:63080582016.PubMed/NCBI
48	Asa SL, Kovacs K, Vale W, Petrusz P and Vecsei P: Immunohistologic localization of corticotrophin-releasing hormone in human tumors. Am J Clin Pathol. 87:327–333. 1987. View Article : Google Scholar : PubMed/NCBI
49	Lemoinne S, Baudel JL, Galbois A, Offenstadt G and Maury E: Suddzith Cushing's Syndrome. Open Endocrinol J. 4:1–2. 2014. View Article : Google Scholar
50	Takeuchi M, Sato J, Manaka K, Tanaka M, Matsui H, Sato Y, Kume H, Fukayama M, Iiri T, Nangaku M and Makita N: Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome. Endocr J. 66:547–554. 2019. View Article : Google Scholar : PubMed/NCBI
51	Atmaca M, Temiz C, Sebile DH, Dökmetaș M and Kiliçli F: A rare cause of ectopic cushing syndrome: Prostate cancer. Endocr Abstr. 70:EP3482020.
52	Bloomer Z, Teague J and Vietor N: Ectopic Cushing's From metastatic prostate cancer. J Endocr Soc. 5:A7572021. View Article : Google Scholar
53	Nadal R, Schweizer M, Kryvenko ON, Epstein JI and Eisenberger MA: Small cell carcinoma of the prostate. Nat Rev Urol. 1:213–219. 2014. View Article : Google Scholar : PubMed/NCBI
54	Rojas-Corona RR, Chen L and Mahadevia PS: Prostatic carcinoma with endocrine features. A report of a neoplasm containing multiple immunoreactive hormonal substances. Am J Clin Pathol. 88:759–762. 1987. View Article : Google Scholar : PubMed/NCBI
55	Abrahamsson PA, Wadström LB, Alumets J, Falkmer S and Grimelius L: Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract. 182:298–307. 1987. View Article : Google Scholar : PubMed/NCBI
56	Jarett L, Lacy PE and Kipnis DM: Characterization by immunofluorescence of an Acth-like substance in nonpituitary tumors from patients with hyperadrenocorticism. J Clin Endocrinol Metab. 24:543–549. 1964. View Article : Google Scholar : PubMed/NCBI
57	Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE and Bonnin JM: Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med. 112:1100–1105. 1988.PubMed/NCBI
58	Capella C, Usellini L, Buffa R, Frigerio B and Solcia E: The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate. Histochemical and ultrastructural identification of the endocrine cells. Histopathology. 5:175–192. 1981. View Article : Google Scholar : PubMed/NCBI
59	Shahani S, Nudelman RJ, Nalini R, Kim HS and Samson SL: Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: A case report and review of the literature. Diagn Pathol. 5:562010. View Article : Google Scholar : PubMed/NCBI
60	di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate diagnostic, prognostic, and therapeutic implications. Cancer. 70 (1 Suppl):S254–S268. 1992. View Article : Google Scholar
61	Parimi V, Goyal R, Poropatich K and Yang XJ: Neuroendocrine differentiation of prostate cancer: A review. Am J Clin Exp Urol. 2:273–285. 2014.PubMed/NCBI
62	Hong MK, Kong J, Namdarian B, Longano A, Grummet J, Hovens CM, Costello AJ and Corcoran NM: Paraneoplastic syndromes in prostate cancer. Nat Rev Urol. 7:681–692. 2010. View Article : Google Scholar : PubMed/NCBI
63	Nadal R, Schweizer M, Kryvenko ON, Epstein JI and Eisenberger MA: Small cell carcinoma of the prostate. Nat Rev Urol. 11:213–219. 2014. View Article : Google Scholar : PubMed/NCBI